GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (NAS:BCLI) » Definitions » Price-to-Free-Cash-Flow

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 30, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Brainstorm Cell Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-30), Brainstorm Cell Therapeutics's share price is $0.5396. Brainstorm Cell Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.49. Hence, Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

BCLI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.61
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Brainstorm Cell Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.06. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.49.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 5.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -8.10% per year.

During the past 13 years, Brainstorm Cell Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 43.30% per year. The lowest was -524.90% per year. And the median was -4.80% per year.


Brainstorm Cell Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Price-to-Free-Cash-Flow Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Brainstorm Cell Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow falls into.



Brainstorm Cell Therapeutics Price-to-Free-Cash-Flow Calculation

Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.5396/-0.489
=N/A

Brainstorm Cell Therapeutics's Share Price of today is $0.5396.
Brainstorm Cell Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Brainstorm Cell Therapeutics  (NAS:BCLI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Brainstorm Cell Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Executives
Stacy Lindborg officer: EVP, Head Global Clin Research C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Nir Naor director BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Kirk Taylor officer: Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Menghisteab Bairu director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Alla Patlis officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Anthony Waclawski officer: See Remarks C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019
Chaim Lebovits officer: Chief Executive Officer 110 EAST 59TH STREET, NEW YORK NY 10019
David Setboun officer: EVP and COO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019
Acc International Holdings Ltd. other: Member of 10% owner group MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110
Sankesh Abbhi director 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134
Jacob A Frenkel director 188 E. 70TH ST., #29A, NEW YORK NY 10021
Arturo Araya officer: Chief Commercial Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Preetam Shah officer: EVP, CFO and Treasurer C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Ralph Dr. Kern officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601
Irit Arbel director 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000

Brainstorm Cell Therapeutics (Brainstorm Cell Therapeutics) Headlines

From GuruFocus